Cellular Biomedicine Group Opens New GMP Facility in Beijing
November 09 2015 - 9:00AM
Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the
“Company”), a biomedicine firm engaged in the development of
effective treatments for degenerative and cancerous diseases, today
announced the opening of its new state-of-the-art facility in the
PKUCare Industrial Park, Changping District, Beijing, China.
Eight hundred square meters of the 1,400 square meter site has been
equipped with four independent production lines to support clinical
batch production and commercial scale manufacturing. Designed and
built to GMP standards, the facility has been certified by the
Beijing Institute for Drug Control, accredited bodies of the China
National Accreditation Service (CNAS) and
China Metrology Accreditation (CMA). With this expansion
into Beijing, the Company now operates three GMP facilities in
China that will house nine independent production lines with the
capacity to host more than 200,000 individual cell sources.
“We feel this is the opportune time for this
expansion into Beijing as we prepare for increasing manufacturing
demands to supply cell therapy materials for more research and
clinical trials from our immuno-oncology, especially CAR-T therapy,
and mesenchymal progenitor cell (haMPC) programs,” said Dr. Richard
L. Wang, Chief Operating Officer for the Company. Our
multi-national team of seasoned scientists is proud to see the
implementation of our vertically integrated research and
development and production systems in several locations. With
patented processes and technologies applied to every step of our
cellular medicine platform spanning sample collection and
processing, cell expansion, banking, shipping and application, we
are able to deliver consistent quality measures across China, which
we believe will better serve our patient population in the
future.”
About Cellular Biomedicine
GroupCellular Biomedicine Group, Inc. develops proprietary
cell therapies for the treatment of certain degenerative and
cancerous diseases. Our developmental stem cell and
Immuno-Oncology projects are the result of research and development
by scientists and doctors from China and the United
States. Our flagship GMP facility in China, consisting of nine
independent cell production lines, is designed, certified and
managed according to U.S. standards. To learn more about
CBMG, please visit: www.cellbiomedgroup.com
Forward-Looking
StatementsStatements in this press release relating to
plans, strategies, trends, specific activities or investments, and
other statements that are not descriptions of historical facts may
be forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include risks
inherent in doing business, trends affecting the global economy,
including the devaluation of the RMB by China in August 2015 and
other risks detailed from time to time in CBMG’s reports filed with
the Securities and Exchange Commission, quarterly reports on form
10-Q, current reports on form 8-K and annual reports on form 10-K.
Forward-looking statements may be identified by terms such as
“may,” “will,” “expects,” “plans,” “intends,” “estimates,”
“potential,” or “continue,” or similar terms or the negative of
these terms. Although CBMG believes the expectations reflected in
the forward-looking statements are reasonable, they cannot
guarantee that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to
update these forward-looking statements other than as required by
law.
Contacts:
Sarah Kelly
Director of Corporate Communications, CBMG
+1 408 973-7884
sarah.kelly@cellbiomedgroup.com
Vivian Chen
Managing Director Investor Relations, Grayling
+1 347 481-3711
vivian.chen@grayling.com
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Apr 2023 to Apr 2024